China Still Leading Vaccines Race Despite Moderna Data, US 'Warp Speed' Plan?

Four In Phase I/II Vs Two From US

The unveiling of US president Donald Trump’s 'Warp Speed’ plan to fast-track a coronavirus vaccine and the latest promising Phase I data from Moderna's candidate haven't seemed to swing China’s belief that it’s still leading the race.

China USA or United States trade and American tariffs conflict with two opposing trading partners as an economic import and exports dispute concept with 3D illustration elements
CHINA, US RACING TO HAVE FIRST CORONAVIRUS VACCINES ON THE MARKET • Source: Shutterstock

The US plan to have a coronavirus vaccine ready by the end of the year, unveiled on 15 May by President Donald Trump, has many wondering if the race to develop such a product is heating up considerably, given that on 18 May one of the leading developers, US firm Moderna Inc., disclosed positive preliminary results from a Phase I trial for its mRNA-based vaccine.

The recent developments are further stirring up a debate over whether the US is getting ahead of China, which started...

More from COVID-19

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By 

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By 

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By 

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

More from Scrip

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

Quotables: Pharma Leaders On The Month’s Hot Topics

 

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

Cipla Revs Up Biosimilars Engine Amid Winds Of Regulatory Change

 

Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.